Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer

Table 4 Clinical outcome and immunological response

Patients	Vaccination course	RECIST	PFS† (DAY)	OS§ (DAY)	T cell response					After treatment
					LY6K	TTK	CDCA1	R1	R2
1	1	PD	15	112	-	++		-	++	None
2	1	PD	29	36	-	+		-	++	None
3	1	PD	43	53	-	+		++	+	None
4	1	PD	33	33	-	-		-	-	None
5	2	PD	53	398	-	-		-	-	EGFR-TKI
6	5	SD	86	834	+	-		-	-	RT
7	1	PD	28	276	-	+		-	++	None
8	4	SD	476	476	+++	+++		+++	+++	None
9	25	SD	400	858	+++	+++		+++	++	None
10	9	SD	200	756	+++		+++	+	+++	EGFR-TKI
11	3	PD	60	265	+++		+++	-	+	None
12	19	SD	490	705*	+++		+++	+++	++	Cx
13	4	PD	53	282	++		++	+	-	None
14	6	SD	83	213	+++		+++	+++	+++	None
15	13	SD	316	571*	+++		+++	+	++	Immune**

*: patients still alive; **: another immunotherapy; †PFS: progression free survival; §OS: overall survival.

ISSN: 1479-5876